Monitoring of MRP-like activity in human erythrocytes: Inhibitory effect of isoflavones

Malgorzata Bobrowska-Hägerstrand, Anna Wróbel, Blaej Rychlik, Grzegorz Bartosz, Thomas Söderström, Yoshiaki Shirataki, Noboru Motohashi, J. Molnár, Krystyna Michalak, Henry Hägerstrand

Research output: Article

36 Citations (Scopus)

Abstract

A method to fluorometrically monitor efflux of 2′,7′-bis-(carboxypropyl)-5(6)-carboxyfluorescein (BCPCF) from human erythrocytes was developed. Genistein, daidzein, sophoraisoflavone A, and licoisoflavone A induced 50% inhibition (IC50) of BCPCF efflux at 15-70μM. The IC50 value of the most efficient isoflavone, licoisoflavone A (15-25 μM), was comparable to that of indomethacin (-10μM) and markedly lower than for probenecid (100-200 μM), both known MRP1 inhibitors. Our results indicate that the human erythrocyte is a useful cell model in screening potential MRP inhibitors, that BCPCF is a good substrate for MRP, and that some isoflavones at low concentrations inhibit MRP-mediated efflux.

Original languageEnglish
Pages (from-to)894-900
Number of pages7
JournalBlood Cells, Molecules, and Diseases
Volume27
Issue number5
DOIs
Publication statusPublished - 2001

Fingerprint

Isoflavones
Human Activities
Erythrocytes
Probenecid
Genistein
Indomethacin
6-carboxyfluorescein
licoisoflavone A

ASJC Scopus subject areas

  • Molecular Biology
  • Molecular Medicine
  • Hematology

Cite this

Bobrowska-Hägerstrand, M., Wróbel, A., Rychlik, B., Bartosz, G., Söderström, T., Shirataki, Y., ... Hägerstrand, H. (2001). Monitoring of MRP-like activity in human erythrocytes: Inhibitory effect of isoflavones. Blood Cells, Molecules, and Diseases, 27(5), 894-900. https://doi.org/10.1006/bcmd.2001.0459

Monitoring of MRP-like activity in human erythrocytes : Inhibitory effect of isoflavones. / Bobrowska-Hägerstrand, Malgorzata; Wróbel, Anna; Rychlik, Blaej; Bartosz, Grzegorz; Söderström, Thomas; Shirataki, Yoshiaki; Motohashi, Noboru; Molnár, J.; Michalak, Krystyna; Hägerstrand, Henry.

In: Blood Cells, Molecules, and Diseases, Vol. 27, No. 5, 2001, p. 894-900.

Research output: Article

Bobrowska-Hägerstrand, M, Wróbel, A, Rychlik, B, Bartosz, G, Söderström, T, Shirataki, Y, Motohashi, N, Molnár, J, Michalak, K & Hägerstrand, H 2001, 'Monitoring of MRP-like activity in human erythrocytes: Inhibitory effect of isoflavones', Blood Cells, Molecules, and Diseases, vol. 27, no. 5, pp. 894-900. https://doi.org/10.1006/bcmd.2001.0459
Bobrowska-Hägerstrand M, Wróbel A, Rychlik B, Bartosz G, Söderström T, Shirataki Y et al. Monitoring of MRP-like activity in human erythrocytes: Inhibitory effect of isoflavones. Blood Cells, Molecules, and Diseases. 2001;27(5):894-900. https://doi.org/10.1006/bcmd.2001.0459
Bobrowska-Hägerstrand, Malgorzata ; Wróbel, Anna ; Rychlik, Blaej ; Bartosz, Grzegorz ; Söderström, Thomas ; Shirataki, Yoshiaki ; Motohashi, Noboru ; Molnár, J. ; Michalak, Krystyna ; Hägerstrand, Henry. / Monitoring of MRP-like activity in human erythrocytes : Inhibitory effect of isoflavones. In: Blood Cells, Molecules, and Diseases. 2001 ; Vol. 27, No. 5. pp. 894-900.
@article{4a7b27ad7a00478f8dd7c5ccb27dbd54,
title = "Monitoring of MRP-like activity in human erythrocytes: Inhibitory effect of isoflavones",
abstract = "A method to fluorometrically monitor efflux of 2′,7′-bis-(carboxypropyl)-5(6)-carboxyfluorescein (BCPCF) from human erythrocytes was developed. Genistein, daidzein, sophoraisoflavone A, and licoisoflavone A induced 50{\%} inhibition (IC50) of BCPCF efflux at 15-70μM. The IC50 value of the most efficient isoflavone, licoisoflavone A (15-25 μM), was comparable to that of indomethacin (-10μM) and markedly lower than for probenecid (100-200 μM), both known MRP1 inhibitors. Our results indicate that the human erythrocyte is a useful cell model in screening potential MRP inhibitors, that BCPCF is a good substrate for MRP, and that some isoflavones at low concentrations inhibit MRP-mediated efflux.",
keywords = "BCPCF, DIDS, Erythrocyte, Indomethacin, Isoflavonoid, Multidrug resistance, Probenecid",
author = "Malgorzata Bobrowska-H{\"a}gerstrand and Anna Wr{\'o}bel and Blaej Rychlik and Grzegorz Bartosz and Thomas S{\"o}derstr{\"o}m and Yoshiaki Shirataki and Noboru Motohashi and J. Moln{\'a}r and Krystyna Michalak and Henry H{\"a}gerstrand",
year = "2001",
doi = "10.1006/bcmd.2001.0459",
language = "English",
volume = "27",
pages = "894--900",
journal = "Blood Cells, Molecules, and Diseases",
issn = "1079-9796",
publisher = "Academic Press Inc.",
number = "5",

}

TY - JOUR

T1 - Monitoring of MRP-like activity in human erythrocytes

T2 - Inhibitory effect of isoflavones

AU - Bobrowska-Hägerstrand, Malgorzata

AU - Wróbel, Anna

AU - Rychlik, Blaej

AU - Bartosz, Grzegorz

AU - Söderström, Thomas

AU - Shirataki, Yoshiaki

AU - Motohashi, Noboru

AU - Molnár, J.

AU - Michalak, Krystyna

AU - Hägerstrand, Henry

PY - 2001

Y1 - 2001

N2 - A method to fluorometrically monitor efflux of 2′,7′-bis-(carboxypropyl)-5(6)-carboxyfluorescein (BCPCF) from human erythrocytes was developed. Genistein, daidzein, sophoraisoflavone A, and licoisoflavone A induced 50% inhibition (IC50) of BCPCF efflux at 15-70μM. The IC50 value of the most efficient isoflavone, licoisoflavone A (15-25 μM), was comparable to that of indomethacin (-10μM) and markedly lower than for probenecid (100-200 μM), both known MRP1 inhibitors. Our results indicate that the human erythrocyte is a useful cell model in screening potential MRP inhibitors, that BCPCF is a good substrate for MRP, and that some isoflavones at low concentrations inhibit MRP-mediated efflux.

AB - A method to fluorometrically monitor efflux of 2′,7′-bis-(carboxypropyl)-5(6)-carboxyfluorescein (BCPCF) from human erythrocytes was developed. Genistein, daidzein, sophoraisoflavone A, and licoisoflavone A induced 50% inhibition (IC50) of BCPCF efflux at 15-70μM. The IC50 value of the most efficient isoflavone, licoisoflavone A (15-25 μM), was comparable to that of indomethacin (-10μM) and markedly lower than for probenecid (100-200 μM), both known MRP1 inhibitors. Our results indicate that the human erythrocyte is a useful cell model in screening potential MRP inhibitors, that BCPCF is a good substrate for MRP, and that some isoflavones at low concentrations inhibit MRP-mediated efflux.

KW - BCPCF

KW - DIDS

KW - Erythrocyte

KW - Indomethacin

KW - Isoflavonoid

KW - Multidrug resistance

KW - Probenecid

UR - http://www.scopus.com/inward/record.url?scp=0035210534&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035210534&partnerID=8YFLogxK

U2 - 10.1006/bcmd.2001.0459

DO - 10.1006/bcmd.2001.0459

M3 - Article

C2 - 11783953

AN - SCOPUS:0035210534

VL - 27

SP - 894

EP - 900

JO - Blood Cells, Molecules, and Diseases

JF - Blood Cells, Molecules, and Diseases

SN - 1079-9796

IS - 5

ER -